January 2018 Issue Table Of Contents

From The Editor

• CEO Tenure: When Is It Time To Move On?

Feature Articles

• Can Joseph Papa Save Valeant?
• Not a Bad Year, After All
• Christi Shaw: Empathy Key To Transforming The Patient Experience
• Industry Explorers Blaze On: Pat Andrews

Capitol Perspectives

• CMS Opens Path To Reform Of Part D

CEO Corner

• The Emergence Of New Gene Therapy Hubs

Companies To Watch

• Daré Bioscience

Industry Research

• What Drives CRO Preferred Provider Selection?

Inside The Industry

• Creating A Contingency Plan: Top 4 Pharma Concerns As Brexit Approaches
• A Celgene Exec's Unexpected Trip To Washington, D.C.
• Breaking The Mold — A New Perspective On Alzheimer’s
• One Small Startup’s Quest For Funding Gets Creative
• 5 Leadership Questions For Camilla Harder Hartvig
• Recurring Mistakes (And Remedies) For Life Sciences M&As
•  

Industry Leader

• Classifying Independent Contractors: 3 Things Pharma CEOs Should Know
• In M&A, The Devil's In The Details ... Of Your Insurance Policy

Leadership Lessons

• Unleashing Breakthrough Innovation

Ask The Board

• Why Does It Seem Academia Is Moving Away From Participating In Clinical Trials, And What Could Be Done To Bring Them Back Into The Fold?
• How Can Biopharmaceutical Companies Be More Successful When Working With Payors In The Future?